CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers

Federica Turdo, Francesca Bianchi, Patrizia Gasparini, Marco Sandri, Marianna Sasso, Loris De Cecco, Luca Forte, Patrizia Casalini, Piera Aiello, Lucia Sfondrini, Roberto Agresti, Maria Luisa Carcangiu, Ilaria Plantamura, Gabriella Sozzi, Elda Tagliabue, Manuela Campiglio

Research output: Contribution to journalArticle

Abstract

CDCP1, a transmembrane noncatalytic receptor, the expression of which has been associated with a poor prognosis in certain epithelial cancers, was found to be expressed in highly aggressive triple-negative breast cancer (TNBC) cell models, in which it promoted aggressive activities-ie, migration, invasion, anchorage-independent tumor growth, and the formation of vascular-like structures in vitro. By immunohistochemical (IHC) analysis of 100 human TNBC specimens, CDCP1 was overexpressed in 57% of samples, 38% of which exhibited a gain in CDCP1 copy number by fluorescence in situ hybridization (FISH). CDCP1 positivity was significantly associated between FISH and IHC. CDCP1 expression and gains in CDCP1 copy number synergized with nodal (N) status in determining disease-free and distant disease-free survival. The hazard ratios (HRs) of the synergies between CDCP1 positivity by IHC and FISH and lymph node positivity in predicting relapse did not differ significantly, indicating that CDCP1 overexpression in human primary TNBCs, regardless of being driven by gains in CDCP1, is for a critical factor in the progression of N-positive TNBCs. Thus, CDCP1 is a novel marker of the most aggressive N-positive TNBCs and a potential therapeutic target.

Original languageEnglish
Pages (from-to)69649-69665
Number of pages17
JournalOncotarget
Volume7
Issue number43
DOIs
Publication statusPublished - 2016

Fingerprint

Triple Negative Breast Neoplasms
Fluorescence In Situ Hybridization
Disease-Free Survival
Blood Vessels
Neoplasms
Lymph Nodes
Recurrence
Growth
Therapeutics

Keywords

  • CDCP1
  • CDCP1 copy number
  • Metastasis
  • Prognosis
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Turdo, F., Bianchi, F., Gasparini, P., Sandri, M., Sasso, M., De Cecco, L., ... Campiglio, M. (2016). CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers. Oncotarget, 7(43), 69649-69665. https://doi.org/10.18632/oncotarget.11935

CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers. / Turdo, Federica; Bianchi, Francesca; Gasparini, Patrizia; Sandri, Marco; Sasso, Marianna; De Cecco, Loris; Forte, Luca; Casalini, Patrizia; Aiello, Piera; Sfondrini, Lucia; Agresti, Roberto; Carcangiu, Maria Luisa; Plantamura, Ilaria; Sozzi, Gabriella; Tagliabue, Elda; Campiglio, Manuela.

In: Oncotarget, Vol. 7, No. 43, 2016, p. 69649-69665.

Research output: Contribution to journalArticle

Turdo, F, Bianchi, F, Gasparini, P, Sandri, M, Sasso, M, De Cecco, L, Forte, L, Casalini, P, Aiello, P, Sfondrini, L, Agresti, R, Carcangiu, ML, Plantamura, I, Sozzi, G, Tagliabue, E & Campiglio, M 2016, 'CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers', Oncotarget, vol. 7, no. 43, pp. 69649-69665. https://doi.org/10.18632/oncotarget.11935
Turdo, Federica ; Bianchi, Francesca ; Gasparini, Patrizia ; Sandri, Marco ; Sasso, Marianna ; De Cecco, Loris ; Forte, Luca ; Casalini, Patrizia ; Aiello, Piera ; Sfondrini, Lucia ; Agresti, Roberto ; Carcangiu, Maria Luisa ; Plantamura, Ilaria ; Sozzi, Gabriella ; Tagliabue, Elda ; Campiglio, Manuela. / CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers. In: Oncotarget. 2016 ; Vol. 7, No. 43. pp. 69649-69665.
@article{6f9ffa300c0b42ae97027c8aa27ba844,
title = "CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers",
abstract = "CDCP1, a transmembrane noncatalytic receptor, the expression of which has been associated with a poor prognosis in certain epithelial cancers, was found to be expressed in highly aggressive triple-negative breast cancer (TNBC) cell models, in which it promoted aggressive activities-ie, migration, invasion, anchorage-independent tumor growth, and the formation of vascular-like structures in vitro. By immunohistochemical (IHC) analysis of 100 human TNBC specimens, CDCP1 was overexpressed in 57{\%} of samples, 38{\%} of which exhibited a gain in CDCP1 copy number by fluorescence in situ hybridization (FISH). CDCP1 positivity was significantly associated between FISH and IHC. CDCP1 expression and gains in CDCP1 copy number synergized with nodal (N) status in determining disease-free and distant disease-free survival. The hazard ratios (HRs) of the synergies between CDCP1 positivity by IHC and FISH and lymph node positivity in predicting relapse did not differ significantly, indicating that CDCP1 overexpression in human primary TNBCs, regardless of being driven by gains in CDCP1, is for a critical factor in the progression of N-positive TNBCs. Thus, CDCP1 is a novel marker of the most aggressive N-positive TNBCs and a potential therapeutic target.",
keywords = "CDCP1, CDCP1 copy number, Metastasis, Prognosis, Triple-negative breast cancer",
author = "Federica Turdo and Francesca Bianchi and Patrizia Gasparini and Marco Sandri and Marianna Sasso and {De Cecco}, Loris and Luca Forte and Patrizia Casalini and Piera Aiello and Lucia Sfondrini and Roberto Agresti and Carcangiu, {Maria Luisa} and Ilaria Plantamura and Gabriella Sozzi and Elda Tagliabue and Manuela Campiglio",
year = "2016",
doi = "10.18632/oncotarget.11935",
language = "English",
volume = "7",
pages = "69649--69665",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "43",

}

TY - JOUR

T1 - CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers

AU - Turdo, Federica

AU - Bianchi, Francesca

AU - Gasparini, Patrizia

AU - Sandri, Marco

AU - Sasso, Marianna

AU - De Cecco, Loris

AU - Forte, Luca

AU - Casalini, Patrizia

AU - Aiello, Piera

AU - Sfondrini, Lucia

AU - Agresti, Roberto

AU - Carcangiu, Maria Luisa

AU - Plantamura, Ilaria

AU - Sozzi, Gabriella

AU - Tagliabue, Elda

AU - Campiglio, Manuela

PY - 2016

Y1 - 2016

N2 - CDCP1, a transmembrane noncatalytic receptor, the expression of which has been associated with a poor prognosis in certain epithelial cancers, was found to be expressed in highly aggressive triple-negative breast cancer (TNBC) cell models, in which it promoted aggressive activities-ie, migration, invasion, anchorage-independent tumor growth, and the formation of vascular-like structures in vitro. By immunohistochemical (IHC) analysis of 100 human TNBC specimens, CDCP1 was overexpressed in 57% of samples, 38% of which exhibited a gain in CDCP1 copy number by fluorescence in situ hybridization (FISH). CDCP1 positivity was significantly associated between FISH and IHC. CDCP1 expression and gains in CDCP1 copy number synergized with nodal (N) status in determining disease-free and distant disease-free survival. The hazard ratios (HRs) of the synergies between CDCP1 positivity by IHC and FISH and lymph node positivity in predicting relapse did not differ significantly, indicating that CDCP1 overexpression in human primary TNBCs, regardless of being driven by gains in CDCP1, is for a critical factor in the progression of N-positive TNBCs. Thus, CDCP1 is a novel marker of the most aggressive N-positive TNBCs and a potential therapeutic target.

AB - CDCP1, a transmembrane noncatalytic receptor, the expression of which has been associated with a poor prognosis in certain epithelial cancers, was found to be expressed in highly aggressive triple-negative breast cancer (TNBC) cell models, in which it promoted aggressive activities-ie, migration, invasion, anchorage-independent tumor growth, and the formation of vascular-like structures in vitro. By immunohistochemical (IHC) analysis of 100 human TNBC specimens, CDCP1 was overexpressed in 57% of samples, 38% of which exhibited a gain in CDCP1 copy number by fluorescence in situ hybridization (FISH). CDCP1 positivity was significantly associated between FISH and IHC. CDCP1 expression and gains in CDCP1 copy number synergized with nodal (N) status in determining disease-free and distant disease-free survival. The hazard ratios (HRs) of the synergies between CDCP1 positivity by IHC and FISH and lymph node positivity in predicting relapse did not differ significantly, indicating that CDCP1 overexpression in human primary TNBCs, regardless of being driven by gains in CDCP1, is for a critical factor in the progression of N-positive TNBCs. Thus, CDCP1 is a novel marker of the most aggressive N-positive TNBCs and a potential therapeutic target.

KW - CDCP1

KW - CDCP1 copy number

KW - Metastasis

KW - Prognosis

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84994245939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994245939&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11935

DO - 10.18632/oncotarget.11935

M3 - Article

AN - SCOPUS:84994245939

VL - 7

SP - 69649

EP - 69665

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 43

ER -